Key facts
- It has raised $3.1M; the latest was Later Stage VC ($150K) in Mar 2025.
- Notable investors include Texas Medical Center.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NativeCardio
- ·The full record, as it builds
Funding rounds
No funding rounds for NativeCardio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NativeCardio
Developer of minimally invasive cardiac therapy devices designed for managing postoperative atrial fibrillation and other heart rhythm disorders. The company offers low-dose, precise, and painless cardioversion therapy, integrates with clinical workflows, reduces the need for high-risk drugs or external procedures, and enables hospitals and cardiac care providers to improve patient outcomes, shorten recovery times, and lower treatment-related complications.
- Sector
- Healthcare
- HQ
- Naples, FL, United States
- Founded
- 2018
- Employees
- 2
- Website
- nativecardio.com/
- Ownership
- Privately Held (backing)
NativeCardio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NativeCardio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NativeCardio in its N-PORT filings yet. We sweep new filings monthly.